Anti-HER2 therapy may also induce an immune response. This chapter addresses the history of research regarding HER2 expression in DCIS as well as ongoing clinical trials that address whether HER2-targeted therapy will improve patient outcomes in DCIS....
[4]Nakada T,Sugihara K,Jikoh T,et al.The Latest Research and Development into the Antibody-Drug Conjugate,[fam-]Trastuzumab Deruxtecan(DS-8201a),for HER2 Cancer Therapy.Chem Pharm Bull(Tokyo).2019;67(3):173-185. [5]Ogitani Y,Aid...
dual anti-HER2 regimenpertuzumabtrastuzumabbreast cancerneoadjuvantIntroduction: The integration of anti-HER2 targeted therapy with chemotherapy has demonstrated an increase in pathologic complete response rates (pCR) in patients with HER2-positive early-stage breast cancer (EBC). This study presents real-...
"While S1613 showed that anti-HER2 therapy was better tolerated and similarly efficacious to anti-EGFR therapy, the key finding is that the relative benefit of these therapies may depend on the level of HER2 amplification. Patients with higher levels of HER2 amplification appeared to benefit more ...
[4] Nakada T, Sugihara K, Jikoh T, et al. The Latest Research and Development into the Antibody-Drug Conjugate, [fam-] Trastuzumab Deruxtecan (DS-8201a), for HER2 Cancer Therapy. Chem Pharm Bull (Tokyo). 2019;67(3):173-185. ...
concurrentHER2amplification. Here we showed that the chromosome 17q23 amplification in the HER2+ breast cancer results in aberrant elevation of WIP1 and miR-21, which not only contributes to breast tumorigenesis, but also causes resistance to anti-HER2 therapy. Therefore, targeted inhibition of WIP...
COMBINATION drug therapyDYSPNEAEPIDERMAL growth factorHOSPITAL emergency servicesHuman epidermal growth factor receptor 2 (HER2)-targeted antibodies, including pertuzumab and trastuzumab, improve overall survival and progression-free survival among women with HER2-positive metastatic breast cancer, but grade 鈥...
The sole use of single modality data often fails to capture the complex heterogeneity among patients, including the variability in resistance to anti-HER2 therapy and outcomes of combined treatment regimens, for the treatment of HER2-positive gastric can
Anti-HER2 Therapy in Elderly Breast Cancer Patients 来自 掌桥科研 喜欢 0 阅读量: 11 作者:Sawaki,Masataka 摘要: Targeting anti-HER-2 therapy, trastuzumab, Lapatinib, T-DM1, and Pertuzumab is a standard therapy for HER-2-overexpressing breast cancer. But there are less data available related to...
HER2 passive immunotherapy, motivated the development of various anti-HER2 vaccine strategies with different limitations (Table1). Indeed, the use in patients of a vaccine that induces or stimulates a pre-existing anti-HER2 immune response offers several advantages (Table1) when compared with passive...